Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | USP7 | Q93009 | 2/20 | 0.48 |
| ▸ | ATR | Q13535 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27664415 | 0.83 | MAPT (0.56) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL319097 | 0.78 | MEN1 (0.48) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27729738 | 0.78 | MAP4K4 (0.50) | MAPTNPC1RAB9APOLBATR | |
| SCHEMBL11907464 | 0.77 | ATR (0.47) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25053115 | 0.74 | JAK3 (0.57) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7705979 | 0.72 | ALDH1A1 (0.58) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3462149 | 0.71 | ATR (0.67) | TP53NPC1RAB9ASMN1; SMN2STAT1 | |
| SCHEMBL14606449 | 0.71 | MAPT (0.58) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3786463 | 0.70 | NQO2 (0.73) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1749196 | 0.70 | MEN1 (0.59) | TP53MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | TP53 59/4885MAPT 4106/4885NPC1 4325/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | TP53 59/4885MAPT 4106/4885NPC1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.